CellCentric, a biotech company developing a novel oral drug for cancer, has raised $220.0M in Series D funding. The substantial capital infusion will advance Inobrodib, its lead candidate, which is the first small molecule drug in the clinic targeting the twin proteins p300 and CBP.
Currently in Phase I/II clinical trials, Inobrodib is being evaluated as an oral capsule for specific solid tumors and haematological malignancies, addressing major unmet clinical needs. The round drew investment from a syndicate including Venrock Healthcare Capital Partners, Fidelity Management & Research Company, Sofinnova Partners, and Pfizer.
